Berkeley Lights, which provides a single cell manipulation platform for drug discovery and development, raised $178 million by offering 8.1 million shares at $22, above the upwardly revised range of $19 to $20. The company offered 0.7 million more shares than anticipated. It originally planned to offer 7.4 million shares at a range of $16 to $18 before increasing the range on Thursday. At pricing, Berkeley Lights commands a fully diluted market cap of $1.5 billion.
Berkeley Lights plans to list on the Nasdaq under the symbol BLI. J.P. Morgan, Morgan Stanley, and Cowen acted as lead managers on the deal.
